DRG Epidemiology's coverage of bladder cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of bladder cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
DRG Epidemiology's bladder cancer forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with bladder cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with bladder cancer per year?
  • How will improvements in survival change the number of people living with a diagnosis of bladder cancer?
  • How will decreasing recurrence risk change the number of people diagnosed with bladder cancer per year?
  • Of all people diagnosed with bladder cancer, how many in each country across the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of bladder cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following bladder cancer patient populations:

  • Bladder Cancer Diagnosed Incident Cases
  • Diagnosed Incident Cases by Muscle Invasiveness at Diagnosis
  • Diagnosed Incident Cases by Stage at Diagnosis
  • Locally Recurrent Incidence
  • Second Local Recurrence Events
  • Third Local Recurrence Events
  • Metastatic Recurrent Incidence
  • Drug-refractory status subpopulation(s)
  • Non-Muscle Invasive Bladder Cancer Drug-Treatable Population
  • Localized and Resectable Locally Advanced Muscle Invasive Bladder Cancer Drug-Treatable Population
  • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer Drug-Treatable Population

… and many more (details available on request).
Note: coverage may vary by country and region.

Table of contents

  • Europe
    • Introduction
      • Key Findings
      • Overview
        • Incidence of Bladder cancer per 100,000 per Year Among People of All Ages in 2017 and 2037
        • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Bladder cancer over the Next Twenty Years
        • Analysis of Diagnosed Incident Cases of Bladder Cancer Across the Countries Under Study in 2017 by Stage
        • Number of Incident Cases of Bladder cancer Avoided Over the Period 2017-2037 Across the Countries Under Study Due to Trends in Risk
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases
      • Newly Diagnosed Incidence
      • Stage and Risk Group at Diagnosis
      • Locally Recurrent Incident Cases
      • Stage Progression Status
      • Drug-Refractory Local Recurrence
      • Metastatic Recurrent Incident Cases
      • Drug-Treatable Populations
      • Drug-Treated Populations
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Nishant Kumar, MPH

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


Related Reports

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

The 2016/17 FDA ap...

View Details

Bladder Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU5)

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape...

View Details

Bladder Cancer | Geographic Focus: China | China In-Depth

Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period...

View Details

Bladder Cancer | Disease Landscape and Forecast | G7 | 2019

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details